Source: Virtual Congress 2020 – Microbiology and antimicrobial strategies in cystic fibrosis
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
G. Tetz (New York, United States of America), K. Kardava (Saint Petersburg, Russian Federation), T. Gembitskaya (Saint Petersburg, Russian Federation), M. Vecherkovskaya (Saint Petersburg, Russian Federation), V. Tetz (Saint Petersburg, Russian Federation). Clinical efficacy data for new diagnostic tool for the selection of the most effective antibiotics for patients with cystic fibrosis. 699

Member's Comments

No comment yet.

Related content which might interest you: The role of inhaled antibiotics in bronchial infection Source: Eur Respir Monogr 2013; 60: 120-126 Year: 2013 Clinical response to elexacaftor/tezacaftor/ivacaftor for cystic fibrosis patients in a compassionate use setting Source: Virtual Congress 2020 – Clinical monitoring and new therapies for cystic fibrosis Year: 2020 Use of a new feedback tool to optimize inhaled aerosol therapy in patients with cystic fibrosis Source: Eur Respir J 2006; 28: Suppl. 50, 261s Year: 2006 Can different approaches to anti-inflammatory therapy result in different outcomes in cystic fibrosis patients? Source: Annual Congress 2007 - Cystic fibrosis lung disease: what do we measure? What do we know? Year: 2007 Health-economic aspects of cystic fibrosis screening and therapy Source: Eur Respir Monogr 2014; 64: 304-319 Year: 2014 Aspergillus pulmonary disease in cystic fibrosis (CF) patients: multicentre perspective observational study based on new diagnostic tests to evaluate the prognostic value on the CF disease Source: Virtual Congress 2021 – Adult cystic fibrosis Year: 2021 A combinational approach to optimize biomarkers efficacy in identifying patients with sarcoidosis and monitoring respiratory functional worsening Source: Annual Congress 2012 - Diffuse parenchymal lung disease IV Year: 2012 A new era in idiopathic pulmonary fibrosis: considerations for future clinical trials Source: Eur Respir J 2015; 46: 243-249 Year: 2015 Ivacaftor-as effective in clinical practice? Source: International Congress 2016 – Cystic fibrosis: various aspects Year: 2016 Assessment of NuvoAir platform use on clinical outcomes in adults with cystic fibrosis: a first Italian experience Source: Virtual Congress 2021 – Cystic fibrosis Year: 2021 Clinical phenotyping of COPD patients: a simple tool with prognosis value Source: International Congress 2018 – COPD phenotypes: a1 antitrypsin deficiency and beyond Year: 2018 Use of an electronic monitoring system to generate objective information on patients’ adherence to taking treatments of a novel inhaled tobramycin solution Source: Annual Congress 2013 –Cystic fibrosis: clinical problems, genetics and microbiology in children Year: 2013 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021 The role of imagistic and functional methods in severity evaluation in children with cystic fibrosis Source: Annual Congress 2007 - Cystic fibrosis: better diagnosis, improved progress, but long-term complications Year: 2007 Comparative efficacy of different methods of ceftazidime administration in children with cystic fibrosis Source: Eur Respir J 2001; 18: Suppl. 33, 126s Year: 2001 Applying sputum as a diagnostic tool in pneumonia - limited yield, minimal impact on treatment decisions Source: Eur Respir J 2001; 18: Suppl. 33, 502s Year: 2001 Update on new treatments for cystic fibrosis Source: Virtual Congress 2020 – Updates in cystic fibrosis Year: 2020 Personalised CFTR pharmacotherapeutic response testing and therapy of cystic fibrosis Source: Eur Respir J, 51 (6) 1702457; 10.1183/13993003.02457-2017 Year: 2018 Cystic fibrosis microbiology, emerging pathogens and more treatment options Source: International Congress 2018 – PG10 Cystic fibrosis: Basic defects and clinical problems in children Year: 2018 Genomically-guided therapies: a new era for cystic fibrosis Source: Virtual Congress 2020 – European Reference Network for rare lung diseases (ERN-LUNG): acting for improved cross-border management of rare diseases Year: 2020